DPOG

Dutch Pharmacology Oncology Group

Publicaties vanuit de DPOG

Tyrosinekinaseremmers

Verheijen RB, Atrafi F, Schellens JHM, Beijnen JH, Huitema ADR, Mathijssen RHJ, Steeghs N. Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. Clin Pharmacokinet. 2017 Jul 31. doi: 10.1007/s40262-017-0582-9. 

Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clin Pharmacol Ther. 2017 Jul 12. doi: 10.1002/cpt.787

Van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, et al. Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options. Clin Pharmacokinet. 2017;56(7):683-8.

Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. Clin Pharmacokin. 2017 Feb 10. doi: 10.1007/s40262-017-0510-z

Apellaniz-Ruiz M, Diekstra MH, Roldan JM, Boven E, Castellano D, Gelderblom H, et al. Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. Pharmacogenet Genomics. 2017;27(6):227-31.

Beukhof CM, van Doorn L, Visser TJ, Bins S, Visser WE, van Heerebeek R, et al. Sorafenib-induced changes in thyroid hormone levels in patients treated for hepatocellular carcinoma. J Clin Endocrinol Metab. 2017.

Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, et al. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol. 2017.

Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, et al. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. Clin Pharmacokinet. 2017;56(3):293-303.

Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, et al. Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients. Clin Cancer Res. 2016;22(23):5738-46.

Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, et al. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry. Ther Drug Monit. 2016;38(6):649-56.

Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, et al. The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. J Clin Pharmacol. 2016;56(10):1307-12.

Desar IM, van Herpen CM, van Erp NP, Kaal SE, van de Kerkhof PC, van der Graaf WT. A successful approach to overcome imatinib-induced skin toxicity in a GIST patient. Anticancer Drugs. 2016;27(6):576-9.

Kloth JS, Hamberg P, Mendelaar PA, Dulfer RR, van der Holt B, Eechoute K, et al. Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment. Eur J Cancer. 2016;56:101-6.

Diekstra MH, Liu X, Swen JJ, Boven E, Castellano D, Gelderblom H, et al. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2015;71(12):1477-84.

van Kinschot CM, van Erp NP, Feberwee T, Dezentje VO. Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery. Eur J Clin Pharmacol. 2015;71(10):1279-81.

Lankhorst S, Baelde HJ, Kappers MH, Smedts FM, Hansen A, Clahsen-van Groningen MC, et al. Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib. Hypertension. 2015;66(3):543-9.

Lankheet NA, Schaake EE, Burgers SA, van Pel R, Beijnen JH, Huitema AD, et al. Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy. Clin Lung Cancer. 2015;16(4):320-4.

de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van Deursen M, Labots M, et al. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. Ther Drug Monit. 2015;37(3):331-8.

Kloth JS, Pagani A, Verboom MC, Malovini A, Napolitano C, Kruit WH, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011-6.

Dubbelman AC, Rosing H, Nijenhuis C, Huitema AD, Mergui-Roelvink M, Gupta A, et al. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Invest New Drugs. 2015;33(1):233-40.

de Wit D, Guchelaar HJ, den Hartigh J, Gelderblom H, van Erp NP. Individualized dosing of tyrosine kinase inhibitors: are we there yet? Drug Discov Today. 2015;20(1):18-36.

Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH, et al. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension. 2014;64(6):1282-9.

van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15(8):e315-26.

Diekstra MH, Klumpen HJ, Lolkema MP, Yu H, Kloth JS, Gelderblom H, et al. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Ther. 2014;96(1):81-9.

Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, et al. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer. 2014;110(10):2441-9.

Lankheet NA, Knapen LM, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Ther Drug Monit. 2014;36(3):326-34.

Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014;53(4):305-25.

Kloth JS, Klumpen HJ, Yu H, Eechoute K, Samer CF, Kam BL, et al. Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. Clin Pharmacokinet. 2014;53(3):261-9.

de Wit D, Gelderblom H, Sparreboom A, den Hartigh J, den Hollander M, Konig-Quartel JM, et al. Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. Cancer Chemother Pharmacol. 2014;73(1):87-96.

Lankheet NA, Huitema AD, Mallo H, Adriaansz S, Haanen JB, Schellens JH, et al. The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. Eur J Clin Pharmacol. 2013;69(12):2065-72.

Sprowl JA, Mathijssen RH, Sparreboom A. Can erlotinib ameliorate cisplatin-induced toxicities? J Clin Oncol. 2013;31(27):3442-3.

Eechoute K, Fransson MN, Reyners AK, de Jong FA, Sparreboom A, van der Graaf WT, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res. 2012;18(20):5780-7.

Chemotherapie

Nijenhuis CM, Lucas L, Rosing H, Huitema ADR, Mergui-Roelvink M, Jamieson GC, et al. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II. Invest New Drugs. 2017;35(4):478-90.

Nieuweboer AJ, de Graan AM, Hamberg P, Bins S, van Soest RJ, van Alphen RJ, et al. Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study. Clin Cancer Res. 2017;23(7):1679-83.

Janssen A, Verkleij CPM, van der Vlist A, Mathijssen RHJ, Bloemendal HJ, Ter Heine R. Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer. Br J Cancer. 2017;116(10):1312-7.

van Doorn L, Veelenturf S, Binkhorst L, Bins S, Mathijssen R. Capecitabine and the Risk of Fingerprint Loss. JAMA Oncol. 2017;3(1):122-3.

Azaro A, Rodon J, Machiels JP, Rottey S, Damian S, Baird R, et al. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function. Cancer Chemother Pharmacol. 2016;78(6):1185-97.

Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krahenbuhl MD, van Geel RM, et al. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. Br J Clin Pharmacol. 2016;82(3):706-16.

de Morree E, van Soest R, Aghai A, de Ridder C, de Bruijn P, Ghobadi Moghaddam-Helmantel I, et al. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation. Prostate. 2016;76(10):927-36.

Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, et al. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine. Cancer Chemother Pharmacol. 2016;77(6):1201-7.

Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, et al. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur Urol. 2015;68(6):939-45.

van Soest RJ, Nieuweboer AJ, de Morree ES, Chitu D, Bergman AM, Goey SH, et al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2015;51(17):2562-9.

Nieuweboer AJ, Smid M, de Graan AJ, Elbouazzaoui S, de Bruijn P, Martens JW, et al. Predicting paclitaxel-induced neutropenia using the DMET platform. Pharmacogenomics. 2015;16(11):1231-41.

Kraff S, Nieuweboer AJ, Mathijssen RH, Baty F, de Graan AJ, van Schaik RH, et al. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother Pharmacol. 2015;75(5):975-83.

Crombag MR, de Vries Schultink AH, Schellens JH, Beijnen JH, Huitema AD. Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study. Drugs Aging. 2014;31(10):737-47.

van Hasselt JG, van Calsteren K, Heyns L, Han S, Mhallem Gziri M, Schellens JH, et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann Oncol. 2014;25(10):2059-65.

Nieuweboer AJ, Hu S, Gui C, Hagenbuch B, Ghobadi Moghaddam-Helmantel IM, Gibson AA, et al. Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res. 2014;74(11):3137-45.

Monoklonale antilichamen

Bins S, van Meerten E, Mathijssen RH. Nivolumab for Squamous-Cell Cancer of Head and Neck. N Engl J Med. 2017;376(6):595-6.

Krens LL, Baas JM, Verboom MC, Paintaud G, Desvignes C, Guchelaar HJ, et al. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction. Cancer Chemother Pharmacol. 2014;73(6):1303-6.

Krens LL, Baas JM, de Jong FA, Guchelaar HJ, Gelderblom H. Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. Cancer Chemother Pharmacol. 2014;73(2):429-33.

Hormonale therapie

Koolen SL, Bins S, Mathijssen RH. Individualized Tamoxifen Dose Escalation-Letter. Clin Cancer Res. 2016;22(24):6300.

Binkhorst L, Bannink M, de Bruijn P, Ruit J, Droogendijk H, van Alphen RJ, et al. Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. Clin Pharmacokinet. 2016;55(2):249-55.

de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clin Pharmacokinet. 2015;54(8):797-810.

Welzen ME, Dezentje VO, van Schaik RH, Colbers AP, Guchelaar HJ, van Erp NP, et al. The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity. Ther Drug Monit. 2015;37(4):501-7.

Binkhorst L, Kloth JSL, de Wit AS, de Bruijn P, Lam MH, Chaves I, et al. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Res Treat. 2015;152(1):119-28.

Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD, Korse TM, et al. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. BMC Cancer. 2013;13:612.

Binkhorst L, van Gelder T, Mathijssen RH. Individualization of tamoxifen treatment for breast carcinoma. Clin Pharmacol Ther. 2012;92(4):431-3.

ter Heine R, Binkhorst L, de Graan AJ, de Bruijn P, Beijnen JH, Mathijssen RH, et al. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. Br J Clin Pharmacol. 2014;78(3):572-86.

Divers

Oosten AW, Abrantes JA, Jonsson S, Matic M, van Schaik RHN, de Bruijn P, et al. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. Clin Pharmacokinet. 2017;56(7):733-46.

Kuip EJ, Zandvliet ML, Koolen SL, Mathijssen RH, van der Rijt CC. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. Br J Clin Pharmacol. 2017;83(2):294-313.

Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H, et al. Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial. J Clin Endocrinol Metab. 2017;102(2):698-707.

Sawicki E, Verheijen RB, Huitema AD, van Tellingen O, Schellens JH, Nuijen B, et al. Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar. Drug Deliv Transl Res. 2017;7(1):125-31.

van Erp NP, van Herpen CM, de Wit D, Willemsen A, Burger DM, Huitema AD, et al. A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. Clin Pharmacokinet. 2016;55(11):1447-56.

de Wit D, Schneider TC, Moes DJ, Roozen CF, den Hartigh J, Gelderblom H, et al. Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. Cancer Chemother Pharmacol. 2016;78(1):63-71.

Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today. 2016;21(6):962-76.

Oosten AW, Abrantes JA, Jonsson S, de Bruijn P, Kuip EJ, Falcao A, et al. Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. Eur J Clin Pharmacol. 2016;72(4):459-67.

van Leeuwen RW, Jansman FG, van den Bemt PM, de Man F, Piran F, Vincenten I, et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015;26(5):992-7.

Mathijssen RH, Sparreboom A, Verweij J. Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol. 2014;11(5):272-81.

Bins S, Ratain MJ, Mathijssen RH. Conventional dosing of anticancer agents: precisely wrong or just inaccurate? Clin Pharmacol Ther. 2014;95(4):361-4.

Opdam FL, Modak AS, Gelderblom H, Guchelaar HJ. Breath tests to phenotype drug disposition in oncology. Clin Pharmacokinet. 2013;52(11):919-26.